Rwanda Biomedical Centre
14
2
2
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
14%
2 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
TETANUS Antibody Detection in Saliva Study
Role: collaborator
Dynamic CDSA to Manage Sick Children in Rwanda
Role: collaborator
Strongyloides Stercoralis Public Health Control in Rwanda
Role: collaborator
Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks
Role: collaborator
Evaluating Scaleup of an Adapted Breast Cancer Early Diagnosis Program in Rwanda
Role: collaborator
Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses
Role: collaborator
Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in Rwanda
Role: lead
Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis
Role: lead
DIAgnostics for Multidrug Resistant Tuberculosis in Africa
Role: collaborator
Estimating the Malaria Prevention Impact of New Nets: Observational Analyses to Evaluate the Evidence Generated During Piloted New Net Distributions in Rwanda
Role: collaborator
Promoting Earlier Detection of Breast Cancer in Rwanda: Scaleup in the National Health Care System
Role: collaborator
Community- and mHealth-Based Integrated Management of Diabetes in Primary Healthcare in Rwanda
Role: collaborator
Evaluation of Clinical Impacts and Costs of eHealth in Rwanda
Role: collaborator
Group Antenatal/Postnatal Care in Rwanda
Role: collaborator
All 14 trials loaded